1YBelow half the group
Rank 43 of 63 funds
Return +16.26%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 43No. 1 is SCBGENOME(E) +62.13%
K Global Healthcare Equity Fund
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
K-GHEALTH invests through the master fund JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD 102.09%
This fundK-GHEALTH
The fund that actually investsJPMorgan Funds – Global Healthcare Fund, Class A (acc) - USDThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY8.17%
ABBVIE ABBV7.45%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per JPMorgan fact sheet
Over the past year it trailed half its group; over 5 years it returned −0.21% per year (Better than half the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +9.43% | +3.16% | +4.24% | +10.47% | +8.19% | +16.50% | +16.26% | +23.39% | −1.02% | +46.67% | +98.72% |
Largest drawdown in the selected period −27.87% Previous peak 20 Feb 2020 (NAV 8.9972) → Trough 23 Mar 2020 (NAV 6.4900) · Back to the previous peak on 18 May 2020, after 1 month
Currently −1.16% from the peak NAV of 11.6833 (5 Nov 2021)
Over 5 years, K-GHEALTH returned -0.01 per unit of volatility, ranking 16 of 33 funds · The highest is FP HCARE-A (0.43)
Paid 2 times in the past 12 months, totalling 0.5000 THB per unit, or 4.33% of NAV
K-GHEALTH pays cash dividends to unitholders from part of the fund's profit. Below is a summary of when you get paid, how much, and how regularly
Holding 1,000 units pays 200.00 THB in dividends · 180.00 THB after 10% withholding tax
THB/unit, totalled by year of payment · * 2026 to 3 Nov 2026
Based on NAV 10.5710 → 11.5479 THB (3 Nov 2025 – 3 Nov 2026) and dividends over the same period
Unitholders' total value doesn't disappear. Part of it moves from the NAV into cash (the example assumes asset prices don't change that day) · See the D markers on the NAV chart
กองทุนมีนโยบายที่จะนำเงินไปลงทุนในต่างประเทศโดยเฉลี่ยรอบระยะเวลาบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน โดยจะเน้นลงทุนในหน่วยลงทุนของกองทุน JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD (กองทุนหลัก) ในอัตราส่วนโดยเฉลี่ยรอบระยะเวลาบัญชีไม่น้อยกว่าร้อยละ 80… Its largest holdings are JP Morgan Funds - Global Healthcare Fund (JPHLUAA LX) 102.09% (fact sheet 30 Sep 2026)
Risk level 6 of 8 (High risk). Since 26 Nov 2014, its NAV has fallen as much as −27.87% from its peak.
Actual total expense ratio (TER) 1.75% a year, against a ceiling of 4.01%. Management fee 1.61%. Front-end fee 1.50%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
Yes. The latest was 0.2000 THB per unit, book close 2 Nov 2026, paid 13 Nov 2026 · 19 payments so far, totalling 4.2000 THB per unit. Dividends are subject to 10% withholding tax and are not guaranteed
Minimum first purchase 500 THB, subsequent purchases 500 THB. Buy orders accepted until 15:30, sell orders until 14:30, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 93.16% of the value of its foreign investments was hedged
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Merck & MRK5.41%
Thermo Fisher TMO4.70%
Novartis NOVN4.59%
AstraZeneca AZN.L4.19%
Unitedhealth Group UNH3.37%
Abbott Laboratories ABT2.96%
Danaher DHR2.96%Eli Lilly and Co LLYDiabetes and weight-loss drugs
ABBVIE ABBVHospitals, medicines and medical equipment
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Merck & MRKHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Novartis NOVNHospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Danaher DHRHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (102.09% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from JPMorgan · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
No. 1 is FP HCARE-A +6.61% per year
| +66.99% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.0 | +0.2 | −5.5 | −0.7 | +2.3 | +6.3 | −0.9 | +2.7 | −2.4 | +8.2 | −0.3 | · | +9.4* |
| 2025 | +6.5 | −0.3 | −2.2 | −3.9 | −4.5 | +1.6 | −0.6 | +2.2 | +0.2 | +5.1 | +7.4 | −1.5 | +9.6 |
| 2024 | +2.0 | +3.0 | +1.9 | −3.9 | +0.3 | +2.7 | +1.5 | +4.3 | −4.9 | −3.3 | −1.7 | −7.4 | −6.0 |
| 2023 | −1.0 | −1.9 | +1.0 | +1.4 | −4.0 | +3.7 | +0.4 | −0.3 | −4.9 | −7.6 | +5.7 | +7.0 | −1.4 |
| 2022 | −10.0 | +0.8 | +8.0 | −6.6 | −2.6 | −1.3 | +4.9 | −3.4 | −2.8 | +3.8 | +1.0 | −1.3 | −10.3 |
THB/unit by book-close date
0 of 19 book-close dates match the SEC dividend history · The rest are inferred from the dates NAV fell by the dividend amount
